The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics has unveiled details of Ficerafusp alfa, a therapy designed to address inadequate tumor penetration in solid tumors, such as head and neck squamous cell carcinoma (HNSCC).
The approach employs two complementary mechanisms: targeting EGFR to focus activity on the tumor and trapping TGF-beta within the tumor microenvironment. This dual strategy aims to enable more effective Tumor Penetration.
View post on X Loading...
Earlier this year, Bicara Therapeutics began the FORTIFI-FLEX trial targeting HPV-negative head and neck cancer with a specific dosing regimen. The company has also scheduled a financial results announcement and business update for November 9. These developments come as the company continues to advance its pipeline for solid tumor therapies.